Background: Cartilage turnover and load-induced tissue changes are frequently assessed by quantifying concentrations of cartilage biomarkers in serum. To date, information on the effects of ultramarathon running on articular cartilage is scarce.
single-stage ultramarathons (distances .42 km without breaks) and multistage ultramarathons (distances .42 km/d over multiple days) are run by fewer athletes per event with races of varying distances. Ultramarathons represent extreme stress for the human body because of not only the duration of the physical activity but also the environmental conditions such as weather and terrain.
The effects of multistage ultramarathons on health have received scientific interest, although the literature is largely limited to effects on the cardiovascular system, 18 respiratory 41 and skeletal muscle, 36 and the gastrointestinal system. 36 Interestingly, to date, information on the effects of ultramarathon running on articular cartilage is scarce. A previous study 35 on a transcontinental multistage footrace over 4486 km reported an initial T2* signal increase during the first 1000 km, followed by a slight decrease throughout the remainder of the race (with medium to high effect sizes) without any morphological or cartilage thickness changes in the ankle joints. These changes were interpreted as an increase in glycosaminoglycan, as observed by Roos and Dahlberg, 30 in the weightbearing posterior medial femoral condyle after moderate
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The American Journal of Sports Medicine, Vol. 45, No. 11 DOI: 10.1177/0363546517712945 Ó 2017 The Author(s) exercise. While these results provide an indication for the ability of the normal cartilage matrix to partially regenerate under ongoing multistage ultramarathon burden in the ankle joints, 35 detailed knowledge on cartilage metabolism in response to extreme running, especially with intermittent, brief recovery periods such as during a multistage ultramarathon, is not available.
Cartilage turnover and load-induced tissue changes are frequently assessed by quantifying concentrations of cartilage biomarkers in serum. Potential cartilage biomarkers include structural proteins or enzymes reflecting cartilage metabolism. For instance, elevated levels of cartilage oligomeric matrix protein (COMP) are associated with a higher risk of knee osteoarthritis (OA), 13 and load-induced changes in serum COMP predict cartilage thickness changes in patients with knee OA. 6 COMP levels are sensitive to exercise bouts of walking ( ). Previous studies have shown that COMP levels continue to increase throughout ultramarathon running races 15, 36 in runners without OA. Hence, load-induced changes in COMP appear to be sensitive to the load magnitude and number of loading cycles during exercise bouts.
Matrix metalloproteinases (MMPs) are a multimember family of proteinases with a wide range of substrates including extracellular components, cytokines, receptors, and cell motility factors. 19, 42 For instance, interstitial collagenase (MMP-1) produced by chondrocytes, osteoblasts, and synovial cells degrades collagen types I, II, and III in the extracellular matrix and mediates cartilage destruction 2, 38 and is expressed at higher levels by OA chondrocytes than by normal chondrocytes suggesting a predominant role of MMP-1 in the pathogenesis of OA. 7, 37 Stromelysin-1 (MMP-3) is in part responsible for the degradation of noncollagen matrix proteins in cartilage in rheumatoid arthritis and OA, 2 and increased levels of MMP-3 and stromelysin-2 (MMP-10) are found in articular cartilage and synovium of these patients. 10, 26, 40 Gelatinase B (MMP-9) and collagenase-3 (MMP-13) coordinate cartilage collagen and aggrecan breakdown. Native collagen type II is degraded by MMP-1, -8, -13, and -14, and partially degraded collagen type II is then further degraded by MMP-2, -9, and -3. 4 Another important cartilage component, and hence relevant in the context of cartilage mechanosensitivity, is collagen type II. In the process of collagen fibril formation, the C-propeptide is removed from procollagen extracellularly and directly reflects the rate of type II procollagen synthesis (CPII). 23 Cleavage of collagen type II by collagenases yields fragments, such as the C2C epitope (COL2-3/4C long mono), 28 reflecting degradation. The purpose of this study was to determine serum changes in cartilage biomarkers during a multistage ultramarathon race. We hypothesized that serum concentrations of COMP, MMP-1, MMP-3, MMP-9, C2C, CPII, and C2C:CPII would increase throughout a multistage ultramarathon. 34 All runners were official race participants meeting the ultramarathon registration requirements: were aged 18 years, had a medical health certificate, and had proof of appropriate ultramarathon running experience. In the 12 months before the race, participants spent a mean 7 to 20 hours per week to run a mean of 50 to 220 km per week. Five participants had a unilateral, focal chondral defect in the patellofemoral joint (femur) and 1 participant in the tibiofemoral joint (tibia) without any symptoms diagnosed by magnetic resonance imaging (MRI), which was performed as part of an associated MRI study on these runners. [33] [34] [35] The MRI signal of these defects did not change throughout the ultramarathon.
METHODS
Serum samples were collected within 4 days before the race (t 0 ) and on days 15 (t 1 : 1002 km), 31 (t 2 : 2132 km), 47 (t 3 : 3234 km), and 58 (t 4 : 4039 km) of the 64-day race. The mean running speed and daily running time for each of the 4 measurement intervals (MI1: t 1 -t 0 ; MI2: t 2 -t 1 ; MI3: t 3 -t 2 ; MI4: t 4 -t 3 ) between blood sampling were calculated and body weight measured for each runner. Blood samples were taken from the cubital vein after the daily running stage. The samples were immediately centrifuged, aliquoted, frozen (below 220°C), and transferred to 280°C after the race. Serum biomarker levels were determined in duplicate using commercial enzyme-linked immunosorbent assays: COMP (Wieslab hCOMP quantitative kit; Euro Diagnostica AB), MMP-1 (RayBio Human MMP-1 ELISA Kit; RayBiotech Inc), MMP-3 and MMP-9 (Human Total MMP-3 Quantikine ELISA Kit and Human Total MMP-9 Quantikine ELISA Kit, respectively; Bio-Techne Corp), and C2C and CPII (Collagen Type II Cleavage Assay and Procollagen Type II C-Propeptide Assay, respectively; IBEX Technologies Inc). All biomarkers were determined simultaneously for each sample upon thawing to avoid refreezing. All samples of each participant were tested on the same plate to avoid any errors due to plate-to-plate differences. Intra-assay variability was assessed as relative coefficients of variation between duplicates and was 4.8% for COMP, 3.7% for MMP-1, 7.0% for MMP-3, 2.7% for MMP-9, 6.9% for C2C, and 7.3% for CPII.
Statistical Analysis
All statistical analyses were performed using SPSS version 21 (IBM Corp). All parameters were tested for normal distribution using Kolmogorov-Smirnov tests. Linear mixed models were used to detect significant changes in serum biomarker levels over time with the time-varying covariates of body weight, running speed, and daily running time.
Because not all runners completed the entire race, missing data were handled by imputing values using the last observation carried forward method, and all models were rerun. Finishing the race was used as a between-participant factor in the models (finisher vs nonfinisher). The significance level for all statistical tests was set a priori to .05.
RESULTS
Participants held a mean running speed of 8.2 6 1.4 km/h and lost a mean of 5.3 6 2.7 kg of body weight (Table 1) . Six runners dropped out in MI2, 1 in MI3, and 4 in MI4. Age, height, body weight, running speed, and biomarker levels after MI1 and MI2 did not differ between the groups by the time of dropout (P . .029). The following reasons for dropout were reported: shin splint (n = 4), thigh splint (n = 2), foot pain with purulence (n = 1), phlegmon finger treated by surgery (n = 1), proximal tibial fracture (n = 1), anterior pelvic ring fracture (n = 1; participant with a focal cartilage defect in the patellofemoral joint), and respiratory infection (n = 1). All other participants with focal cartilage defects completed the race. None of the biomarker results differed between the participants with or without focal cartilage defects.
Serum concentrations of COMP, MMP-9, and MMP-3 changed significantly throughout the multistage ultramarathon (Table 2 ). On average, concentrations increased during MI1 by 22.5% for COMP (95% CI, 0.29-0.71 ng/mL), 22.3% for MMP-3 (95% CI, 0.24-15.37 ng/mL), and 95.6% for MMP-9 (95% CI, 81.7-414.5 ng/mL) and remained stable throughout MI2, MI3, and MI4 ( Figure 1 ). Changes in serum COMP, MMP-3, and MMP-9 concentrations during MI1 did not differ between finishers and nonfinishers (time 3 finishing group interaction: P = .387, P = .620, and P = .945, respectively). Serum concentrations of MMP-1, C2C, CPII, and C2C:CPII did not change significantly throughout the multistage ultramarathon ( Table  2 ). The results of the linear mixed models did not change when the data of nonfinishers were considered using the last observation carried forward approach.
The time-varying covariate of body weight was significantly associated with changes in COMP, MMP-3, and MMP-9 throughout the multistage ultramarathon (COMP: Wald Z = 3.411, P = .002; MMP-3: Wald Z = 2.472, P = .013; MMP-9: Wald Z = 2.226, P = .026). The time-varying covariates of running speed and daily running time were not associated with changes in any cartilage biomarker. Changes in MMP-3 were associated with changes in COMP throughout the ultramarathon race (MMP-3: Wald Z = 3.476, P = .001) in which in 68% of runners, ultramarathoninduced changes in MMP-3 levels explained more than 30% of ultramarathon-induced changes in COMP levels. Figure  2 shows an example of the relationship between MMP-3 and COMP levels for a participant. Changes in MMP-1, MMP-9, C2C, CPII, or C2C:CPII were not associated with changes in COMP.
DISCUSSION
The purpose of this study was to determine serum changes in cartilage biomarkers during a multistage ultramarathon race. COMP, MMP-3, and MMP-9 levels increased within the first 11 days of the ultramarathon race and remained elevated throughout the remainder of the race. Values are expressed as mean 6 SD unless otherwise specified. Boldface indicates statistical significance (P \ .05).
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Results of the linear mixed models on the runners who completed the race (n = 25). The results of the linear mixed models did not change when the data of nonfinishers were considered using the last observation carried forward approach.
MMP-1, C2C, and CPII levels and C2C:CPII did not change throughout the race. The time-varying covariate of body weight was associated with changes in COMP, MMP-3, and MMP-9 throughout the multistage ultramarathon. Changes in MMP-3 were associated with changes in COMP throughout the ultramarathon race. The results provide first evidence that only some cartilage biomarkers are sensitive to extreme running and that changes in these biomarkers are correlated.
Of the known potential cartilage biomarkers, COMP has been used most often as a surrogate measure of cartilage degradation in studies on the effect of exercises of different intensities on articular cartilage. Interestingly, the magnitude of increase in COMP in our study (122.5%) was not greater than that reported for marathon and single-stage ultramarathon races. For instance, COMP levels did not change more than after other physical activities such as walking 14 km uphill 29 ; walking for 30 minutes 20 ; walking 4000 steps at a slow, medium, or fast speed 5 ; or running for 30 minutes. 24 Moreover, increases in COMP after a marathon ranged from 17% to 60%. 15, 21, 22 Kim et al 14, 15 reported a 1.9-and 3-fold increase in COMP levels after 100 km and 200 km, respectively, of a 200-km single-stage ultramarathon in 2 separate studies (mean race time, 32.5 hours). In a single-stage ultramarathon study by Shin et al, 36 COMP levels increased by 130.7% at 100 km to 160.4% at 200 km and 194.1% at 308 km (mean race time, 61.5 hours). All of these studies have in common that COMP serum concentrations continued to increase throughout these single-stage marathon 15, 22 or single-stage ultramarathon races. 14, 15, 36 In contrast, serum COMP levels in our study remained stable throughout the multistage ultramarathon race after the initial 1002 km. Because the second blood draw was taken 15 days into the race (after 1002 km), information regarding a potential, initial continuous increase or a peak in the COMP level between days 1 and 11 of the race is not available.
Previous studies have reported a recovery of COMP levels within 30 minutes to several days for light (30-minute walking 20 or running 24 ) and intense exercise (marathons 15, 21, 22 and ultramarathons 15 ), respectively. Moreover, Mü ndermann et al 21 have shown that COMP levels Figure 1 . Mean relative changes in cartilage biomarkers normalized to baseline levels. C2C, C-terminal neoepitope generated by the collagenase-mediated cleavage of collagen type II triple helix; C2C:CPII, ratio of C2C and CPII reflecting collagen turnover; COMP, cartilage oligomeric matrix protein; CPII, procollagen type II C-terminal propeptide; MMP, matrix metalloproteinase. Values are expressed as mean 6 SD unless otherwise specified. Boldface indicates statistical significance (P \ .05). C2C, C-terminal neoepitope generated by the collagenase-mediated cleavage of collagen type II triple helix; C2C:CPII, ratio of C2C and CPII reflecting collagen turnover; COMP, cartilage oligomeric matrix protein; CPII, procollagen type II C-terminal propeptide; MMP, matrix metalloproteinase. Results of the linear mixed models on the runners who completed the race (n = 25). The results of the linear mixed models did not change when the data of nonfinishers were considered using the last observation carried forward approach. in runners with faster marathon finishing times return to prerace levels within 24 hours of the marathon but not in those with slower marathon finishing times. The authors attributed these differences to different relative loads between runners because of the greater number of steps taken during the race in slower runners or differences in fitness among runners. In addition, a predefined walking exercise (4000 steps) at varying speeds (slow, medium, fast) resulted in systematic changes in COMP levels, and these changes were related to differences in joint mechanics. 5 Accordingly, one could expect that changes in COMP during a multistage ultramarathon are associated with the running speed and/or daily running time. However, the linear mixed models with time-varying covariates did not reveal such an association in this group of experienced ultramarathon runners. Interestingly, a 3-week multistage cycling race did not result in changes in COMP levels in professional cyclists. 3 As with running, cycling is characterized by high cyclic joint loads (eg, several times the body weight at the knee 16 ), but unlike running, joint forces rise and fall without an impact peak caused by collisions of the body with the ground. The lack of changes in COMP levels in a multistage cycling race and increases in COMP levels in a multistage running race suggest that COMP levels are sensitive to repetitive impact loads, most likely of articular cartilage and not of other musculoskeletal tissue.
The main differences between single-stage and multistage ultramarathons are the much longer distances covered and the daily (usually overnight) resting times in multistage races. On the basis of COMP data from marathons and single-stage ultramarathons, one would expect the magnitude of changes in COMP levels to increase with increasing distance, with a gradual increase in levels throughout a race. The fact that COMP levels did not increase more during the multistage ultramarathon than reported increased values in shorter single-stage races suggests that the daily resting time may have been sufficient for tissue recovery to some extent. Slower runners took more time each day to complete the daily stage and hence had shorter overnight resting times, implying less recovery. However, daily running time was not associated with changes in COMP. Hence, even in slower runners, overnight resting times may have been sufficient for preventing further increases in COMP levels throughout the race. It appears that cartilage reached a steady state during the race, which is further supported by previous reports 33, 35 of an initial T2* increase in articular cartilage of the ankle and the knee, followed by a subsequent T2* decrease (ankle) 35 and steady state (knee) 33 in these runners. The changes in COMP levels reported here support the previous suggestion of the ability of the normal cartilage matrix at the ankle joints to partially regenerate with continuing multistage ultramarathon loading. 35 Participants of multistage ultramarathon races represent a unique sample of athletes who are extremely well conditioned because of extreme training regimens, possibly explaining the smaller increases in COMP levels compared with those reported in marathon and single-stage ultramarathon runners. These results are relevant not only for ultramarathon runners but also for elite athletes training for marathons requiring high weekly running distances or for extreme expeditions of several days or weeks.
Cyclic loading enhances COMP expression in a fully developed pericellular matrix. 9 While some data on the effects of running on COMP are available, little is known on the effects of running on other cartilage biomarkers. COMP levels are a measure of intact COMP or COMP fragments in blood. However, it is unclear if these fragments are present because of simple turnover or cartilage breakdown. Hence, markers reflecting tissue metabolism must also be considered. MMP-3 and MMP-9 levels but not MMP-1, C2C, or CPII levels changed during the multistage ultramarathon. Interestingly, COMP, MMP-3, and MMP-9 but not MMP-1 levels changed during immobilization during a 21-day bed rest study (Liphardt A-M, Mü ndermann A, Koo S, et al. Relevance of immobility for serum levels of biomarkers for cartilage health. Paper presented at: 19th IAA Humans in Space Conference; June 7-12 2014; Waterloo, Ontario, Canada). Hence, COMP, MMP-3, and MMP-9 systematically respond to extreme loading and to unloading, emphasizing their importance in the mechanobiology of articular cartilage. MMP-3 is in part responsible for the degradation of noncollagen matrix proteins in cartilage in rheumatoid arthritis and OA, 2 and MMP-9 and MMP-13 coordinate cartilage collagen and aggrecan breakdown. The association of changes in MMP-3 levels with changes in COMP levels indicates that MMP-3 may be involved in the degradation of COMP. This result supports findings of in situ experiments in which the digestion of human articular cartilage with MMP-3, -12, or -13 but not with MMP-2, -8, or -9 yielded fragments of COMP. 43 MMP-1 degrades collagen types I, II, and III in the extracellular matrix and mediates cartilage destruction. 2, 38 The lack of changes in MMP-1, C2C, and CPII levels and in C2C:CPII suggests that extreme running loads did not affect collagen turnover. Similarly, COMP, MMP-3, and MMP-9 but not MMP-1 levels changed in a 21-day bed rest study, 17 suggesting that MMP-1 is not sensitive to loading.
Henrotin et al 12 observed decreases in Coll2-1 (a denaturation epitope located in the triple helical domain of the collagen type II molecule that is made available by unwinding of the triple helix 11 ) levels after a marathon, which they interpreted as a protective effect of long-distance running on cartilage. In contrast, we did not observe changes in C2C or CPII levels or in C2C:CPII during the multistage ultramarathon, suggesting that the balance between collagen type II synthesis and degradation was unaffected by the extreme running load. However, because the second sample was taken after about 1000 km, it is possible that we were unable to detect subtle changes early in the race. Moreover, it is possible that extreme loading does not initiate collagen turnover but causes reorganization or loss of organization of the matrix and degradation of proteoglycans, resulting in an increase in glycosaminoglycan content, 30, 31 which has also been indicated by previously observed changes in T2* of articular cartilage at the ankle during a multistage ultramarathon. 35 Some discrepancies between our results and the literature may have been caused by methodological differences. For instance, while many studies used a blood sample taken within 2 hours before the race as a baseline value, in other studies, baseline samples were taken 24 hours before a marathon, 39 6 to 10 hours before an ultramarathon, 15 and up to 4 days before the multistage ultramarathon in our study. Moreover, none of the studies specified whether physical activity before the baseline sample was controlled or restricted, which may influence baseline levels. 20 Interestingly, most studies 14, 15, 21, 36 on marathon and ultramarathon running involved participants with an average age around 50 years who were experienced ultramarathon runners, while 25% of the population between 45 and 64 years of age suffer from arthritis or joint pain.
1 Some runners had a focal lesion in the patellofemoral joint without any symptoms, and the MRI signal did not change throughout the race. Hence, the patellofemoral joint may not have been adversely affected by extreme running on flat ground. Further, it is possible that only athletes without any joint degeneration affecting joint mechanics will participate in such a physically and mentally demanding sport. On the basis of the literature, it is also feasible that a stringent training regimen over a long time may protect against cartilage degeneration in the tibiofemoral and ankle joints, as previously shown in animal studies 8, 27 and suggested by Schü tz et al. 35 
CONCLUSION
The results of this study provide evidence that physical loading affects some cartilage biomarkers (COMP, MMP-9, and MMP-3 but not MMP-1, C2C, CPII, or C2C:CPII) and that the magnitude of these changes appears to be limited by providing regular short recovery periods throughout ultrarunning exercises in highly adapted endurance athletes. While COMP levels may play an important role in the mechanotransduction of ambulatory loads to chondrocytes, the role of COMP serum concentrations on cartilage health in this population remains unclear. Nonetheless, elevated COMP levels indicate increased COMP turnover in response to extreme running, and the association between load-induced changes in MMP-3 and changes in COMP suggests the possibility that MMP-3 may be involved in the degradation of COMP. The lack of changes in MMP-1, C2C, CPII, and C2C:CPII indicates that these markers are not involved in load-induced changes in articular cartilage.
